The Melanoma Nursing Initiative – Home › Forums › Targeted therapy › Other › Adjuvant targeted therapy › Reply To: Adjuvant targeted therapy
May 5, 2018 at 9:03 pm
#4831
I think we are more likely to give immunotherapy adjuvantly. The side affects of dabrafenib especially the pyrexia are very difficult for patients to maintain their normal lifestyle. I think that dabrafenib and tramatenib do have a place adjuvantly with patients who can’t recieve immunotherapy such as those with precious history of colitis or other autoimmune conditions or organ transplant patients.